

Figure 1. On cell binding of anti-MSLN antibodies to CHO cells expressing human MSLN




Figure 2. Activity of anti-CD40 antibodies with and without crosslinking in human B cell assay




Figure 3. Bivalent bispecific antibody formats






Figure 4. Generation of cell lines expressing varying levels of MSLN



MC38.huMSLN clone #	Receptors/Cell
MC38.MSLN5	366043
MC38.MSLN4	207344
MC38.MSLN3	109120
MC38.MSLN2	103593
MC38.MSLN1	9453

Figure 5. Pharmacokinetic properties and stability of anti-CD40xMSLN bispecific molecules in mouse



Antibody ID	CD40 Capture				MSLN Capture			
	Half-life (h)	AUC last (hr*ug/mL)	Vss (mL/kg)	CL (mL/h/kg)	Half-life (h)	AUC last (hr*ug/mL)	Vss (mL/kg)	CL (mL/h/kg)
8766-3	201	1108	174	0.61	197	993	192	0.7
6041-5	193	1998	95	0.36	216	1546	130	0.42
8765-3	269	2009	111	0.29	258	1812	120	0.33
8767-3	124	507	255	1.72	124	483	260	1.81
8945-3	115	1148	119	0.76	125	1206	123	0.7
8947-3	193	1998	95	0.36	199	2101	92	0.34

Figure 6. Generation of MC38-human EPCAM and B16F10-human EPCAM expressing cell line





Figure 7. Activity of mouse surrogate anti-CD40xhuman EPCAM bispecific molecule



Antibody ID	Description	EC50 (nM)
PL-49963	Anti-CD40 (FGK45)	~15
PL-55263	Anti-CD40xhuman EPCAM Bispecific	0.2429




Figure 8. Mouse surrogate anti-CD40xhuman EPCAM bispecific molecule has tumor-localized, TAA-mediated X-linking-dependent activity in vivo




Figure 9. Mouse surrogate anti-CD40xhuman EPCAM bispecific molecule enhances CD8+ T cell anti-tumor responses




Figure 10. Mouse surrogate anti-CD40xhuman EPCAM bispecific molecule has tumor-localized, TAA-mediated X-linking-dependent activity in vivo





Figure 11. Mouse surrogate anti-CD40xhuman EPCAM bispecific molecule does not increase levels of systemic cytokines or increase liver inflammation







Figure 12. Mouse surrogate anti-CD40xhuman EPCAM bispecific molecule induces regression of established MC38-human EPCAM tumors alone and in combination with PD1/PDL1 blockade






Figure 13. Mouse surrogate anti-CD40xhuman EPCAM bispecific molecule induces long-lasting immune memory that protects against tumor re-challenge

